In conclusion, we demonstrated that AE-AS exhibits a potent antiangiogenic activity in bladder cancer through suppressing WSB-1-induced pVHL degradation, HIF-1α induction/activity, and angiogenesis-related signaling pathways. Here, WSB1 is linked to urinary bladder cancer.